

**A - ORIGINAL ARTICLES IN PEER REVIEWED JOURNALS**

(Alphabetisch nach Erstautor sortiert)

1. Ajdacic-Gross V, Knöpfli D, Landolt K, Gostynski M, **Engelter ST, Lyrer PA**, Gutzwiller F, Rössler W. Death has a preference for birthdays-an analysis of death time series. *Ann Epidemiol.* 2012 Aug;22(8):603-6. [Epub ahead of print May 31] PMID 22658822 **IF: 2.95**
2. **Amann M**, Achtnichts L, Hirsch JG, **Naegelin Y**, Gregori J, **Weier K**, Thönl A, **Mueller-Lenke N, Radue EW**, Günther M, **Kappos L, Gass A**. 3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS. *Mult Scler.* 2012 Mar 30. [Epub ahead of print] **IF:4.3**
3. **Amort M, Fluri F**, Weisskopf F, **Gensicke H, Bonati LH, Lyrer PA, Engelter ST**. Etiological Classifications of Transient Ischemic Attacks: Subtype Classification by TOAST, CCS and ASCO - A Pilot Study. *Cerebrovasc Dis.* 2012;33(6):508-16. Epub 2012 Apr 25. **IF: 2.72**
4. **Azakir BA, Di Fulvio S**, Salomon S, Brockhoff M, Therrien C, **Sinnreich M**. Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules. *J Biol Chem.* 2012 Aug 10;287(33):27629-36. doi: 10.1074/jbc.M112.391722. Epub 2012 Jun 26., PMID: 22736764 [PubMed - indexed for MEDLINE] **IF: 4.77**
5. **Azakir BA, Di Fulvio S, Kinter J, Sinnreich M**. Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells. *J Biol Chem.* 2012 Mar 23;287(13):10344-54. Epub 2012 Feb 8. **IF: 4.77**
6. Baumann-Bhalla S, Meier RM, **Burow A, Lyrer P, Engelter S, Bonati L**, Filippi A, Lambrecht JT. Recognizing calcifications of the carotid artery on panoramic radiographs to prevent strokes. *Schweiz Monatsschr Zahnmed.* 2012;122(11):1016-29
7. **Bendfeldt K**, Klöppel S, Nichols TE, Smieskova R, Kuster P, Traud S, **Mueller-Lenke N, Naegelin Y, Kappos L, Radue EW**, Borgwardt SJ. Multivariate pattern classification of gray matter pathology in multiple sclerosis. *Neuroimage.* 2012 Mar;60(1):400-8. **IF: 5.895**
8. **Bendfeldt K**, Hofstetter L, Kuster P, Traud S, **Mueller-Lenke N, Naegelin Y, Kappos L, Gass A**, Nichols TE, Barkhof F, Vrenken H, Roosendaal SD, Geurts JJ, **Radue EW**, Borgwardt SJ. Longitudinal gray matter changes in multiple sclerosis-Differential scanner and overall disease-related effects. *Human Brain Mapp.* 2012 May;33(5):1225-45. **IF: 5.88**
9. Birkenmaier A, Ries J, **Kuhle J**, Bürki N, Lapaire O, Hösli I. Placental  $\alpha$ -microglobulin-1 to detect uncertain rupture of membranes and cost analysis in an European cohort of pregnancies *Arch Gynecol Obstet*, 285 (1), 21-25, 2012 **IF: 1.072**
10. Leo H **Bonati**, Jörg Ederle, Joanna Dobson, **Stefan Engelter**, Roland L Featherstone, Peter A Gaines, Jonathan D Beard, Graham S Venables, Hugh S Markus, Andrew Clifton, Peter Sandercock, Martin M Brown, on behalf of the CAVATAS Investigators. Length of carotid stenosis predicts peri-procedural stroke or death and restenosis in patients randomised to endovascular treatment or endarterectomy. *Int J Stroke* 2012; In print. **IF 2.382**

11. **Bonati LH, Lyrer P**, Ederle J, Featherstone R, Brown MM. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. *Cochrane Database Syst Rev* 2012;9:CD000515. **IF 5.715**
12. Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Caset-Semanaz F, Hennessy B, Stam Moraga M, Rocak S, Stubinski B, **Kappos L**. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. *Lancet Neurol*. 2012 Jan;11(1):33-41. **IF: 23.462**
13. Comi G, Jeffery D, **Kappos L**, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO STUDY GROUP. Placebo-controlled trial of oral laquinimod for multiple sclerosis. *N Engl J Med*. 2012 Mar 15;366(11):1000-9. **IF: 53.3**
14. Carotid Stenting Trialists' Collaboration, Rantner B, Goebel G, Zeumer H, Turner E, Ringleb PA, Mali WP, Chatellier G, Brown MM, Becquemin JP, Algra A, **Bonati LH\***, Fraedrich G\*, Mas JL\* (\* Equal contribution). The risk of carotid artery stenting compared with carotid endarterectomy is greatest in patients treated within 7 days of symptoms. *J Vasc Surg* 2012. 2012 Dec 10 (*Epub ahead of print*). **IF 3.153**
15. Corporaal SH\*, **Gensicke H\***, **Kuhle J**, **Kappos L**, Allum JH, **Yaldizli O**. Balance control in multiple sclerosis: Correlations of trunk sway during stance and gait tests with disease severity. *Gait Posture*. 2012 Aug 5. [*Epub ahead of print*]. **IF: 2.123**
16. De Marchis GM, Katan M, Weck A, **Fluri F**, Foerch C, Findling O, Schuetz P, Buhl D, El-Koussy M, **Gensicke H**, Seiler M, Morgenthaler N, Mattle PH, Mueller B, Christ-Crain M, Arnold M. Copeptin Adds Prognostic Information After Ischemic Stroke: Results From the CoRisk Study. *Neurology*, accepted for publication. November 2012. **IF: 8.31**
17. Devonshire V, Havrdova E, **Radue EW**, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, **Kappos L**; FREEDOMS STUDY GROUP. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. *Lancet Neurol*. 2012 May;11(5):420-8. **IF: 23.462**
18. Duering M, Zieren N, Hervé D, Jouvent E, Reyes S, **Peters N**, Pachai C, Opherk C, Chabriat H, Dichgans M. Strategic role of frontal white matter tracts in vascular cognitive impairment: a voxel-based lesion-symptom mapping study in CADASIL. *Brain*, Epub 2011. **IF: 9.457**
19. **Engelter ST**, **Amort M**, Jax F, Weisskopf F, Katan M, **Burow A**, **Bonati LH**, **Hatz F**, Wetzel SG, **Fluri F**, **Lyrer PA**. Optimizing the risk estimation after a transient ischaemic attack - the ABCDE plus score. *Eur J Neurol* 2012;19:55-61. **IF 3.692**
20. **Engelter ST**, Dallongeville J, Kloss M, Metso TM, Leys D, Brandt T, Samson Y, Caso V, Pezzini A, Sessa M, Beretta S, Debette S, Grond-Ginsbach C, Metso AJ, Thijs V, Lamy C, Medeiros E, Martin JJ, Bersano A, Tatlisumak T, Touzé E, **Lyrer PA**; for the Cervical Artery Dissection and Ischaemic Stroke Patients (CADISP)-Study Group. Thrombolysis in Cervical Artery Dissection - Data from the Cervical Artery Dissection and Ischaemic Stroke Patients (CADISP) database. *Eur J Neurol*. 2012;19: 1199–1206 (doi: 10.1111/j.1468-1331.2012.03704.x) **IF: 3.69**

21. **Engelter ST**, Urscheler N, Baronti F, Vuadens P, Koch J, Frank M, Diserens K, Jenni W. Frequency and Determinants of Using Pharmacological Enhancement in the Clinical Practice of In-Hospital Stroke Rehabilitation. *Eur Neurol*. 2012 Jun 7;68(1):28-33. **IF: 1.81**
22. Fanchamps MH, **Gensicke H, Kuhle J, Kappos L**, Allum JH, **Yaldizli O**. Screening for balance disorders in mildly affected multiple sclerosis patients. *J Neurol*, 259 (7), 2012 **IF: 3.853**
23. Filli L, Hofstetter L, Kuster P, Traud S, **Mueller-Lenke M, Naegelin Y, Kappos L, Gass A, Sprenger T**, Nichols TE, Barkhof F, Polman C, **Radue EW**, Borgwardt SJ, **Bendfeldt K**. Spatiotemporal Distribution of White Matter Lesions: Differences between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. *Mult Scler* 2012;18:1577-84. **IF: 4.3**
24. Fischmann A, **Hafner P**, Gloor M, Schmid M, Klein A, Pohlman U, Waltz T, Gonzalez R, Haas T, Bieri O, **Fischer D**. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. *J Neurol*. 2012 Nov 9. [Epub ahead of print], **IF: 3.473**
25. Fischmann A, Kaspar S, **Reinhardt J**, Gloor M, Stippich C, **Fischer D**. Exercise might bias skeletal-muscle fat fraction calculation from Dixon images. *Neuromuscul Disord*. 2012 Oct 1;22 Suppl 2:S107-10. **IF: 2.797**
26. Fischmann A, **Hafner P**, Fasler S, Gloor M, Bieri O, Studler U, **Fischer D**. Quantitative MRI can detect subclinical disease progression in muscular dystrophy. *J Neurol*. 2012 Aug;259(8):1648-54. **IF: 3.473**
27. **Fluri F**, Jax F, **Amort M**, Wetzel SG, Katan M, **Lyrer PA, Hatz F, Engelter ST**. Significance of microbleeds in patients with transient ischemic attacks. *Eur J Neurol* 2012 Mar;19(3):522-524 **IF: 3.69**
28. Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, **Kappos L**, Olsson TP, Miller A, Benzerdjeb H, LI H, Simonson C, O'Connor PW; Teriflunomidemultiple Sclerosis Trial Group and the MRI Analysis Center. Teriflunomide added to interferon- $\beta$  in relapsing multiple sclerosis: a randomized phase II trial. *Neurology*. 2012 Jun 5;78(23):1877-85. **IF: 8.31**
29. Freedman M, Metzigg C, **Kappos L**, Polman C, Edan G, Hartung HP, Miller D, Montalban X, Yarden J, Spector L, Fire E, Dota N N, Schwenke S, Lanius V, Sandbrink R, Pohl C. Predictive nature of IgM anti- $\alpha$ -glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. *Mult Scler*. 2012 Jul;18(7):966-73. **IF: 4.3**
30. **Gensicke H**, Datta AN, Dill P, Schindler C, **Fischer D**. Increased incidence of Guillain-Barré syndrome after surgery. *Eur J Neurol*. 2012 Sep;19(9):1239-44. Epub 2012 Apr 23. **IF: 3.692**
31. **Gensicke H**, Zumbrunn T, Jongen LM, Nederkoorn PJ, Macdonald S, Gaines PA, **Lyrer PA**, Wetzel SG, van der Lugt A, Mali WP, Brown MM, van der Worp HB, **Engelter ST, Bonati LH**, on behalf of the ICSS-MRI Substudy Investigators. Characteristics of ischaemic brain lesions after stenting or endarterectomy for symptomatic carotid artery stenosis – Results from the ICSS-MRI substudy. *Stroke*. 2012 Dec 13. [Epub ahead of print]. **IF: 5.729**

32. Gold R, **Kappos L**, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; Define Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *N Engl J Med*. 2012 Sep 20;367(12):1098-107. **IF: 53.3**
33. Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, **Kappos L**, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C; Beyond Study Group. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. *Mult Scler*. 2012 Feb;18(2):181-95. **IF: 4.3**
34. Grond-Ginsbach C, Chen B, Pjontek R, Wiest T, Jiang Y, Burwinkel B, Tchatchou S, Krawczak M, Schreiber S, Brandt T, Kloss M, Arnold ML, Hemminki K, Lichy C, **Lyrer PA**, Hausser I, **Engelster ST**. Copy number variants in patients with cervical artery dissection. *Eur J Hum Genet*. 2012 Dec;20(12):1295-9. doi: 10.1038/ejhg.2012.82. PMID: 22617347 **IF: 3.56**
35. **Hardmeier M**, Zimmermann R, Pflüger M, **Rüegg S**, Deuster S, Drewe J, **Fuhr P**, Haschke M. High-dose, fast absorbed intranasal midazolam as a potential treatment for status epilepticus: a pharmacokinetic-pharmacodynamic study in healthy volunteers using quantitative EEG. *Clin Pharmacol Ther* 2012; 91: 856-62. **IF: 6.043**
36. **Hardmeier M**, Schoonheim MM, Geurts JG, Polman Ch, Barkhof F, Stam CJ. Cognitive dysfunction in Multiple Sclerosis: Relation to functional connectivity and Eigenvector centrality derived from resting-state magneto-encephalography (MEG). *PLoS One*. 2012;7(7):e42087. **IF: 4.092**
37. Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A, Kleinschnitz C, Rauer S, **Kuhle J**, Stangel M, Weber F, Uhr M, Linnebank M, Wildemann B, Jarius S, Guger M, Ayzenberg I, Chan A, Zettl U, Wiendl H, Pilz G, Hitzl W, Weber J, Kraus J. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. *Mult Scler*, epub ahead of print, Oct 2012-11-27 **IF: 4.255**
38. Hartung HP, Kieseier B, Goodin DS, Arnason BG, Comi G, Cook S, Filippi M, Jeffery DR, **Kappos L**, Bogumil T, Stemper B, Sandbrink R, Nakada Y, Nakajima H, Schwenke S, Lehr S, Heubach J, Pohl C, Reischl J. Variability in detection and quantification of interferon  $\beta$ -1b-induced neutralizing antibodies. *J Neuroinflammation*. 2012 Jun 15;9:129. **IF: 5.79**
39. Hottinger AL, Sutter R, Marsch S. **Rüegg S**. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: An observational cohort study. *CNS Drugs* 2012; 26: 761-72. **IF 4.795**
40. Inkster B, Strijbis EM, Vounou M, **Kappos L**, **Radue EW**, Matthews PM, Uitdehaag BM, Barkhof F, Polman CH, Montana G, Geurts JJ. Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. *Neurobiol Aging*. 2012 Aug 9. **IF: 6.189**
41. Kamm CP, El-Koussy M, Humpert S, Findling O, Von Bredow F, Burren Y, Schwegler G, Schött D, Donati F, Müller M, Goebels N, Müller F, Slotboom J, Tettenborn B, **Kappos L**, **Naegelin Y**, Mattle HP. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. *J Neurol*. 2012 May 9. [Epub ahead of print] **IF: 3.47**
42. **Kappos L**, Devonshire V, Häring DA. Reporting of subgroup analyses from clinical trials - Author's reply. *Lancet Neurol*. 2012 Sep;11(9):747-8. **IF: 23.46**

43. **Kappos L**, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O'Neill GN. Effect of BG-12 on contrast-enhancing lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. *Mult Scler*. 2012 Mar;18(3):314-21. **IF: 4.255**
44. Kloss M, Metso A, Pezzini A, Leys D, Giroud M, Metso TM, Tatlisumak T, Lichy C, Bersano A, Abboud S, Grau A, **Lyrer PA**, Debette S, Dallongeville J, Martin J, Caso V, Grond-Ginsbach C\*, **Engelster ST\*** for the CADISP Group (\*equal contribution). Towards Understanding Seasonal Variability in Cervical Artery Dissection (CeAD) *J Neurol* 2012;259(8):1662-7 [Epub 2012 Jan 28] **IF: 3.47**
45. Levin J, Högen T, Patzig M, Pfister HW, **Peters N**. Pontine and extrapontine myelinolysis associated with hypernatraemia. *Clin Neurol Neurosurg*. 2012;114(9):1290-1. **IF: 1.581**
46. Lichy C, Metso A, Pezzini A, Leys D, Metso T, **Lyrer P**, Debette S, Thijs V, Abboud S, Kloss M, Samson Y, Caso V, Sessa M, Beretta S, Lamy C, Medeiros E, Bersano A, Touze E, Tatlisumak T, Grau A, Brandt T, **Engelster S**, Grond-Ginsbach C; for the Cervical Artery Dissection and Ischemic Stroke Patients (CADISP)-Study Group. Predictors of delayed stroke in patients with cervical artery dissection. *Int J Stroke*. 2012 Dec 11. doi: 10.1111/j.1747-4949.2012.00954.x. [Epub ahead of print], **IF: 2.38**
47. Meckel S, Leitner L, **Bonati LH**, Santini F, Schubert T, Stalder AF, **Lyrer P**, Markl M, Wetzel SG. Intracranial artery velocity measurement using 4D PC MRI at 3 T: comparison with transcranial ultrasound techniques and 2D PC MRI. *Neuroradiology*. 2012 Nov 10. [Epub ahead of print]. **IF: 2.824**
48. Metso TM, Tatlisumak T, Debette S, Dallongeville J, **Engelster ST**, **Lyrer PA**, Thijs V, Bersano A, Abboud S, Leys D, Grond-Ginsbach C, Kloss M, Touzé E, Pezzini A, Metso AJ. Migraine in cervical artery dissection and ischemic stroke patients *Neurology*. 2012 Apr 17;78(16):1221-1228. PMID:22491867 **IF: 8.31**
49. Metso TM, Debette S, Grond-Ginsbach C, **Engelster ST**, Leys D, Brandt T, Pezzini A, Bersano A, Kloss M, Thijs V, Lyrer PA, Tatlisumak T, Metso AJ. Age-dependent differences in cervical artery dissection. *J Neurol*. 2012 Oct;259(10):2202-10. doi: 10.1007/s00415-012-6485-7. [Epub 2012 Apr 18.] PMID:22527225 **IF: 3.47**
50. Metso AJ, Metso TM, Debette S, Dallongeville J, **Lyrer PA**, Pezzini A, Lichy C, Kloss M, Brandt T, Touzé E, Southerland AM, Worrall BB, Abboud S, Del Zotto E, Leys D, **Engelster S**, Grond-Ginsbach C, Tatlisumak T; for the CADISP group. Gender and cervical artery dissection. *Eur J Neurol*. 2012 Apr;19(4):594-602 **IF: 3.69**
51. Metz I, **Radue EW**, Oterino A, Kümpfel T, Wiendl H, Schippling S, **Kuhle J**, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. *Acta Neuropathol*, 123 (2), 235-245, 2012, **IF: 7.695**
52. Meyer S, Stelveing E, **D'Souza M**, Hug B. Schmerzhaftes Parese und Hautausschlag. *Schweizer Med Forum*
53. Miller AE, O'Connor P, Wolinsky JS, Confavreux C, **Kappos L**, Olsson TP, Truffinet P, Wang L, D'Castro L, Comi G, Freedman MS; for the Teriflunomide Multiple Sclerosis Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMPO) of oral teriflunomide in relapsing multiple sclerosis. *Mult Scler*. 2012 Sep 25. **IF: 4.3**

54. Nardi K, **Engelter S**, Strbian D, Sarikaya H, Arnold M, Casoni F, Ford GA, Cordonnier C, **Lyrer P**, Bordet R, Soenne L, **Gensicke H**, Duriez P, Baumgartner RW, Tatlisumak T, Leys D; On behalf of the Lipid Profile in Thrombolysis Study Group. Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia. *Neurology*. 2012 Sep 11;79(11):1101-8. **IF: 8.31**
55. **Papadopoulou A, Kappos L, Sprenger T**. Teriflunomide for oral therapy in multiple sclerosis. *Expert Review of Clinical Pharmacology*, 2012 Nov;5(6):617-28, **IF: 3.283**
56. **Papadopoulou A**, von Felten S, Traud S, Rahman A, Quan J, King R, Garren H, Steinman **L. Kappos** Evolution of MS lesions to black holes under DNA vaccine treatment, *Journal of Neurology* **IF: 3.473**
57. **Papadopoulou A, Müller-Lenke N, Naegelin Y, Kalt G, Bendfeldt K, Kuster P, Stoceklin M, Gass A, Sprenger T, Radue EW, Kappos L, Penner IK**. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis, *MSJ* **IF: 4.255**
58. **Penner IK, Hubacher M, Rasenack M, Sprenger T, Weber P, Naegelin Y**. Utility of neuropsychological testing for guiding treatment decisions in a patient with pediatric multiple sclerosis. *Mult Scler*, 10.1177/1352458512450355. Epub 2012 Jun 27. **IF: 4.3**
59. **Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink R**. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. *Mult Scler*. 2012 Oct;18(10):1466-71. **IF: 4.3**
60. **Peyer AK**, Kinter J, Hench J, Frank S, **Fuhr P**, Thomann S, Fischmann A, Kneifel S, Camaño P, Munain AL, **Sinnreich M**, Renaud S. Novel valosin containing protein mutation in a Swiss family with hereditary inclusion body myopathy and dementia. *Neuromuscul Disord*. 2012 Nov 7. doi:pii: S0960-8966(12)00608-6. 10.1016/j.nmd.2012.09.009. [Epub ahead of print] **IF: 2.797**
61. Putaala J, Yesilot N, Waje-Andreassen U, Pitkäniemi J, Vassilopoulou S, Nardi K, Odier C, Hofgart G, **Engelter S**, Burow A, Mihalka L, Kloss M, Ferrari J, Lemmens R, Coban O, Haapaniemi E, Maaijwee N, Rutten-Jacobs L, Bersano A, Cereda C, Baron P, Borellini L, Valcarenghi C, Thomassen L, Grau AJ, Palm F, Urbanek C, Tuncay R, Durukan-Tolvanen A, van Dijk EJ, de Leeuw FE, Thijs V, Greisenegger S, Vemmos K, Lichy C, Bereczki D, Csiba L, Michel P, Leys D, Spengos K, Naess H, Bahar SZ, Tatlisumak T. Demographic and Geographic Vascular Risk Factor Differences in European Young Adults With Ischemic Stroke: The 15 Cities Young Stroke Study. *Stroke*. 2012;43(10):2624-30. [Epub ahead of print Jul 12.] **IF: 5.73**
62. **Radue EW**, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, **Mueller-Lenke N**, Agoropoulou C, Holdbrook F, **De Vera A**, Zhang-Auberson L, Francis G, Burtin P, **Kappos L**; for the FTY720 Research evaluating effects of daily oral therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis. *Arch Neurol*. 2012 Jul 2:1-11. doi: 10.1001/archneurol.2012.1051. **IF: 7.584**
63. Regeniter A, **Kuhle J, Baumann T, Sollberger M**, Herdener M, , Kunze U, Camuso MC, Monsch AU. Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA. *Methods*, epub ahead of print, Apr 2012 **IF: 4.011**
64. Rejdak K\*, **Kuhle J\***, **Rüegg S, Lindberg R**, Petzold A, Sulejczak D, Papuc E, Rejdak R, Stelmasiak Z, Grieb P. \* equal contribution. Neurofilament heavy chain and HSP-70 as markers of seizure related brain injury. *Epilepsia*, 53(5), 922-927, 2012 **IF: 3.955**

65. Rigotti DJ, Gass A, Achtnichts L, Inglese M, Babb JS, **Naegelin Y**, Hirsch J, **Amann M**, **Kappos L**, Gonen O Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment. *Mult Scler*. 2012 Jan;18(1):98-107. **IF: 4.3**
66. Ritz MF, Grond-Ginsbach C, **Engelter ST**, **Lyrer PA**. Gene Expression Suggests Spontaneously Hypertensive Rats May Have Altered Metabolism and Reduced Hypoxic Tolerance. *Curr Neurovasc Res*. 2012 Feb;9(1):10-9 [Epub ahead of print Jan 16] **IF: 3.23**
67. **Schlaeger R**, **D'Souza M**, Schindler C, Grize L, Dellas S, **Radue EW**, **Kappos L**, **Fuhr P**. Prediction of long-term disability in multiple sclerosis. *Mult Scler*. 2012 Jan;18(1):31-8. doi: 10.1177/1352458511416836. PMID: 21868486 [PubMed - indexed for MEDLINE] **IF: 4.2**
68. **Schlaeger R**, **D'Souza M**, Schindler C, Grize L, **Kappos L**, **Fuhr P**. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. *Clin Neurophysiol*. 2012 Feb;123(2):406-10. doi: 10.1016/j.clinph.2011.06.021. PMID: 21778106 [PubMed - indexed for MEDLINE] **IF: 3.7**
69. Seifert CL, **Magon S**, Staehle K, Zimmer C, Foerschler A, Tölle TR, **Sprenger T**. A case-control study on cortical thickness in episodic cluster headache. *Headache* 2012;52:1362-1368 **IF: 2.5**
70. Seifert CL, Wegner C, **Sprenger T**, Weber MS, Brück W, Hemmer B, Sellner J. Favorable response to plasma exchange in tumefactive CNS demyelination. *Mult Scler* 2012;18:1045-9. **IF: 4.3**
71. **Seiffge DJ**, Lapina NE, Tsagogiorgas C, Theisinger B, Henning RH, Schilling L.: Improvement of oxygen supply by an artificial carrier in combination with normobaric oxygenation decreases the volume of tissue hypoxia and tissue damage from transient focal cerebral ischemia. *Exp Neurol*. 2012 Sep;237(1):18-25 Epub 2012 Jun 21 **IF: 4.7**
72. **Sievers C**, **Meira M**, **Hoffmann F**, Fontoura P, **Kappos L**, **Lindberg RL**. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. *Clin Immunol*. 2012 Jul;144(1):70-9. **IF: 4.046**
73. Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, **Kappos L**, Kieseier BC, Montalban X, Olsson T. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. *Mult Scler*. 2012 Feb;18(2):143-52. **IF: 4.3**
74. **Sprenger T**, Seifert CL, Valet M, Andreou A, Foerschler A, Zimmer C, Collins L, Goadsby, PJ, Tolle TR, Chakravarty MM. Assessing the risk of central post-stroke pain of thalamic origin by lesion mapping. *Brain* 2012;135:2536-45. **IF 9.5**
75. **Sprenger T**, Seifert CL. Coma after greater occipital nerve blockade in a patient with previous posterior fossa surgery. *Headache*, Epub 2012 Dec 18 **IF 2.5**
76. Sutter R, Tschudin-Sutter S, Grize L, Widmer AF, Marsch S, **Rüegg S**. Infectious complications in status epilepticus – a five year observational cohort study. *Epilepsia* 2012; 53: 1489-97. **IF: 3.961**
77. Sutter R, Mengiardi B, Benz D, Heijnen I, **Kappos L**, **Winkler DT**. Facial nerve palsy and anti-Ku autoantibodies. *J Neurol*. 2012 Feb;259(2):361-3. **IF: 3.47**

78. Strbian D, **Engelter S**, Michel P, Meretoja A, Sekoranja L, Ahlhelm F, Mustanoja S, Kuzmanovic I, Sairanen T, Forss N, Cordier M, **Lyrer P**, Kaste M, Tatlisumak T. Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis: The SEDAN Score, *Annals of Neurology* Volume 71, Issue 5, pages 634–641, May 2012 **IF: 11.089**
79. Strbian D, Meretoja A , Ahlhelm FJ , Pitkäniemi J, Lyrer P., Kaste M, **Engelter ST**, Tatlisumak T. Predicting outcome of iv thrombolysis-treated ischemic stroke patients: The DRAGON Score. *Neurology* 2012 Feb 7;78(6):427-32 **IF: 8.31**
80. Strijbis EM, Inkster B, Vounou M, **Naegelin Y, Kappos L, Radue EW**, Matthews PM, Uitdehaag BM, Barkhof F, Polman CH, Montana G, Geurts JJ. Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. *Mult Scler.* 2012 Jul 31. **IF: 4.3**
81. Sutter R, Tschudin-Sutter S, Grize L, **Fuhr P**, Bonten M, Widmer A, Marsch S, **Rueeg S**. Associations between infections and clinical outcome parameters in status epilepticus: A retrospective 5-year cohort study, *Epilepsia* **IF: 3.961**
82. Sutter R, **Rüegg S**, Kaplan P. Epidemiology, diagnosis, and management of non-convulsive status epilepticus – opening Pandora's Box. *Neurol Clin Pract* 2012; 2: 276-85.
83. Sutter R, **Rüegg S**. Refractory status epilepticus: epidemiology, clinical aspects and Management of a persistent epileptic storm. *Epileptologie* 2012; 29: 186-193.
84. Thalmann R, **Gensicke H, Burow A, Bonati LH, Lyrer A, Engelter S**. Thrombolyse bei Hirnschlag-Patienten: Prognostische Bedeutung von Statinvorbehandlung und Cholesterinprofil. *Swiss Archives of Neurology and Psychiatry.* 2012;163(4):130-7.
85. Vergouwen MD, Compter A, Tanne D, **Engelter ST**, Audebert H, Thijs V, de Freitas G, Algra A, Jaap Kappelle L, Schonewille WJ. Outcomes of basilar artery occlusion in patients aged 75 years or older in the Basilar Artery International Cooperation Study. *J Neurol.* 2012 Apr 18. [Epub ahead of print] PMID: 22527236 **IF: 3.47**
86. **Weier K**, Beck A, **Magon S, Amann M, Naegelin Y, Penner IK**, Thuerling M, Aurich V, **Radue EWR**, Stippich C, **Kappos L**, Timmann D, **Sprenger T**. Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis. *J Neurol* 2012;259:2673-80. **IF 3.5**
87. **Weier K**, Mazraeh J, **Naegelin Y**, Thoeni A, Hirsch JG, Fabbro T, Bruni N, **Duyar H, Bendfeldt K, Radue EW, Kappos L, Gass A**. Biplanar MRI for the assessment of the spinal cord in multiple sclerosis. *Mult Scler.* 2012 Apr 26. **IF: 4.3**
88. **Weier K, Naegelin Y, Amann M, Magon S, Mueller-Lenke N, Radue EW, Kappos L**, Stippich C, **Gass A, Sprenger T**. Six year follow-up of a case-series with non-communicating syringomyelia in Multiple Sclerosis. *European Journal of Neurology*, Epub 2012 Dec 17. **IF 3.7**
89. **Weier K, Naegelin Y, Amann M, Magon S, Andelova M, Mueller-Lenke N, Radue EW**, Stippich C, **Kappos L, Gass A, Sprenger T**. Six year follow up of a case-series with non-communicating syringomyelia in Multiple Sclerosis. *Mult Scler. J* (2012): 18, Suppl. 4, p166. Peer reviewed **IF: 4.3**
90. **Weier K, Penner IK, Magon S, Amann M, Naegelin Y, Mueller-Lenke N**, Beck A, **Andelova M, Derfuss T, Radue EW**, Stippich C, **Kappos L, Sprenger T**. Relation of cerebellar volume to performance in cognitive tests in patients with Multiple Sclerosis. *Mult Scler. J* (2012): 18, Suppl. 4, p12. **IF: 4.3**



91. Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, **Kappos L**, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. *J Neurol*. 2012 May;259(5):898-905. **IF: 3.5**
92. Zieren N, Duering M, **Peters N**, Reyes S, Jouvent E, Hervé D, Gschwendtner A, Mewald Y, Opherck C, Chabriat H, Dichgans M. Education modifies the relation of vascular pathology to cognitive function: cognitive reserve in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. *Neurobiol Aging*. Epub 2012. **IF: 6.189**

## B - BUCHBEITRÄGE, EDITORIALS & REVIEWS 2012

(Alphabetisch nach Erstautor sortiert)

1. **Bonati LH.** Restenosis after carotid artery stenting: remaining issues. *Lancet Neurol* 2012;11:740-1. **IF 23.462**
2. **Bonati LH, Engelter ST, Lyrer PA.** Carotid artery stenting. *Swiss Med Wkly* 2012;142:w13619. **IF 1.895**
3. **Derfuss T, Kappos L.** Evaluating the potential benefit of interferon treatment in multiple sclerosis. *JAMA.* 2012 Jul 18;308(3):290-1. **IF: 30**
4. Fiedler U, Wiltfang J, **Peters N**, Benninghoff J. Fortschritte in der Diagnostik der Alzheimer Demenz. (Advances in the diagnostics of Alzheimer's disease). *Der Nervenarzt* 2012, 83 (5): 661 – 673. **IF: 0.681**
5. **Fischer D.,** Auer-Grumbach M. Autonome Neuropathien *Schweizer Med Forum*
6. Garcia M, **Sprenger T.** Bedeutung des MRI bei der Abklärung rezidivierender Kopfschmerzen. *Info Neurologie & Psychiatrie* 2012;10:6-9.
7. **Gensicke H, Engelter S, Bonati L.** Endovascular treatment for carotid artery stenosis. *Ther Umsch.* 2012 Sep;69(9):523-35.
8. **Gensicke H,** Leppert D, **Yaldizli Ö, Lindberg RL, Mehling M, Kappos L, Kuhle J.** Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis *CNS Drugs.* 2012 Jan 1;26(1):11-37. **IF: 4.8**
9. **Lyrer P, Bonati L,** Patrik Michel. Organisierte Behandlung in einer Stroke Unit – Voraussetzung zur optimierten Behandlung des akuten Hirnschlages, *Ther. Umschau*
10. **Lyrer P.,** Michel P., Arnold M., Hungerbühler H., Gralla J., Humm A., Fandino J., Fischer U., Gasche Y., Kägi G., Liesch M., Lövblad K-L, Luft A., Müller F., Nedeltchev K., Renaud S., Städler C., Bassettid C., Sztajzel R., Weder B., Wetzel S., **Engelter S.** Schweizerische Hirnschlaggesellschaft, Stroke Units und Stroke Centers in der Schweiz: Richtlinien und Anforderungsprofil. *Schweiz Med Forum* 2012;12(47):918–922
11. **Naumann N., Sinnreich M.** Mehr als nur Muskelkater, *Info Neurologie & Psychiatrie*
12. **Peters N,** Benninghoff J. Demenz-Früherkennung. *Der Hausarzt* 2012, 49 (1): 37-40.
13. **Peters N.** Vaskuläre Demenz. *Der bayerische Internist* 2012, 32(3): 12-18.
14. **Peters N,** Opherk O. „Leukodystrophien“. In: Therapie und Verlauf neurologischer Erkrankungen. Hrsg: Brandt, Diener, Gerloff. Kohlhammerverlag, 6. Auflage 2012
15. **Rüegg S,** Roelcke U. Brain tumor-associated seizures: glutamate, transporters and an old drug (Editorial). *Neurology* 2012; 79: 844-5. **IF: 8.312**
16. **Seiffge D,** Ahlhelm F, **Peters N, Bonati L, Lyrer P,** Marugg A, **Rüegg S, Engelter S.** Was ist PRES? *Schweiz Med Forum* 2012, 12 (25): 500-504.
17. **Seiffge DJ., Lyrer P.:** Vorhofflimmern und Sekundärprävention nach Hirnschlag

18. Stellenwert der neuen Antikoagulanzen. *CARDIOVASC 2012/6* und *In|FO|Neurologie & Psychiatrie 2012*
19. **Seiffge DJ, Lyrer P:** Akutmassnahmen bei Hirnschlag. *Der informierte Arzt 08/2012*
20. **Seiffge D, Nedeltchev K, Lyrer P.:** [The new anticoagulants - their role in secondary prevention of thromboembolism after stroke]. *Ther Umsch.* 2012 Sep;69(9):517-22
21. **Sprenger T, Borsook D.** Migraine Changes the Brain – Neuroimaging makes its mark. *Curr Opin Neurol.* 2012;25:252-62. **IF 4.9**
22. **Sprenger T, Kappos L.** Alemtuzumab for multiple sclerosis: who and when to treat? *Lancet.* 2012 Nov 24;380(9856):1795-7 **IF 38.3**
23. **Sprenger T, May A.** Advanced Neuroimaging for the study of migraine pathophysiology. *Pain: Clinical Updates (IASP Press) Vol. XX, Issue 6, October 2012, page 1-7.*
24. **Sprenger T, Seifert, C, Goadsby PJ.** Imaging activation in the migraine state. In: Borsook D, May A, Goadsby PJ, Hargreaves R (eds.). *The Migraine Brain.* Oxford University Press, NY, 2012: p.245-250.
25. Valet M, **Sprenger T, Scheef L, Boecker H.** Psychophysiological Assessments in Physical Exercise: Somatosensory Profiles and Autonomic Nervous System. In: Boecker H, Hillman C, Scheef L, Strüder HK (eds). *Functional Neuroimaging in Exercise and Sport Sciences.* Springer Verlag, NY, 2012, p 155-168
26. Boecker H, Tölle TR, Valet M, **Sprenger T.** Effects of Aerobic Exercise on Mood and Human Opioidergic Activation Measured by Positron Emission Tomography. In: Boecker H, Hillman C, Scheef L, Strüder HK (eds). *Functional Neuroimaging in Exercise and Sport Sciences.* Springer Verlag, NY, 2012, 499-510.
27. **Sprenger T, Goadsby PJ.** Neuroimaging in Headache Disorders. In: Aminoff, Daroff (eds.) *Encyclopedia of Neurological Sciences*, 2nd edition. Elsevier, in press.
28. Stankewitz A\*, **Sprenger T\***, Schulz E. Tölle TR. Positron emission tomography for assessing neuronal activity and metabolism in acute and chronic pain. In Arendt-Nielsen L, Handwerker HH (eds.). *Pain Models: Translational Relevance and Applications*, IASP press, in press. \*equally contributing